fingolimod (FTY720)
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Rett's Syndrome
Conditions
Rett's Syndrome
Trial Timeline
Aug 1, 2013 → Apr 1, 2018
NCT ID
NCT02061137About fingolimod (FTY720)
fingolimod (FTY720) is a phase 1/2 stage product being developed by Novartis for Rett's Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02061137. Target conditions include Rett's Syndrome.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02061137 | Phase 1/2 | Completed |
| NCT01498887 | Approved | Completed |
| NCT00731523 | Phase 1 | Completed |
Competing Products
4 competing products in Rett's Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Esomeprazole + Aspirin + Rofecoxib | AstraZeneca | Approved | 85 |
| Esomeprazole + Lansoprazole | AstraZeneca | Approved | 85 |
| Esomeprazole Magnesium | AstraZeneca | Approved | 85 |
| Chemotherapy | Pacific Biosciences | Pre-clinical | 15 |